Lupin receives USFDA's approval for Ethacrynic Acid Tablets
9th Sep 2019

Lupin has received approval for its Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (USFDA).

The company’s Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc. It is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. Ethacrynic Acid Tablets USP (RLD: Edecrin Tablets) had annual sales of approximately $24 million in the US (IQVIA MAT June 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.